With the advent of novel T-cell-directed therapies and diverse therapeutic classes available for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), it Is more critical than ever to be able to differentiate the unique safety profiles of current and emerging agents to best anticipate, mitigate, and manage treatment-related toxicities. In the final video of this Accelerator Hub, join expert DLBCL faculty as they review the adverse event profiles of different agents used in the treatment of patients with R/R DLBCL, as well as deliver strategies to monitor and manage toxicities to optimize patient outcomes.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/adverse-events-associated-treatments-r-r-dlbcl-anticipating-managing-range
- Start Date: 2024-10-31 05:00:00
- End Date: 2024-10-31 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Pfizer (Any division) - Amount: 45000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest